Kivu Bioscience Raises $92M Series A to Advance Safer, Targeted Cancer Therapies
Biotech firm Kivu Bioscience has secured $92 million in Series A funding, led by Novo Holdings, with additional participation from Gimv, Red Tree Venture Capital, HealthCap, BioGeneration Ventures, M Ventures, and BOM. The investment will support Kivu’s efforts to develop next-generation antibody-drug conjugates (ADCs) aimed at improving cancer treatment by minimizing side effects and increasing … Read more